Home
About
Pricing
Log In

What are you looking for?

Home
Pricing
Back
Compare AU

Compare VAP vs. DRUG

Compare shares and ETFs on the ASX that you can trade on Pearler.

Vanguard Australian Property Securities Index ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard Australian Property Securities Index ETF (VAP) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

VAP

DRUG

Popularity

Low

Low

Pearlers invested

917

80

Median incremental investment

$1,000.00

$736.96

Median investment frequency

Monthly

Monthly

Median total investment

$2,612.61

$2,210.88

Average age group

> 35

> 35

Key Summary

VAP

DRUG

Strategy

VAP seeks to track the performance of the S&P/ASX 300 A-REIT Index before considering any additional expenses.

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 184.38m in AUM and 55 holdings. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

Top 3 holdings

Goodman Group (27.19 %)

Scentre Group (11.28 %)

Stockland (7.79 %)

AUD - AUSTRALIA DOLLAR (0 %)

BRL - BRAZILIAN REAL (0 %)

CHF - SWISS FRANC (0 %)

Top 3 industries

Real Estate (99.39 %)

Other (0.61 %)

Other (75.91 %)

Communication Services (33.53 %)

Health Care (23.80 %)

Top 3 countries

Australia (100.00 %)

United States (72.30 %)

Switzerland (11.31 %)

United Kingdom of Great Britain and Northern Ireland (5.57 %)

Management fee

0.23 %

0.57 %

Key Summary

VAP

DRUG

Issuer

Vanguard

BetaShares

Tracking index

S&P/ASX 300 A-REIT Index - AUD

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

Asset class

ETF

ETF

Management fee

0.23 %

0.57 %

Price

$90.09

$9.87

Size

$2.976 billion

$199.202 million

10Y return

31.53 %

110.45 %

Annual distribution yield (5Y)

4.11 %

1.82 %

Market

ASX

ASX

First listed date

15/10/2010

08/08/2016

Purchase fee

$6.50

$6.50

Community Stats

VAP

DRUG

Popularity

Low

Low

Pearlers invested

917

80

Median incremental investment

$1,000.00

$736.96

Median investment frequency

Monthly

Monthly

Median total investment

$2,612.61

$2,210.88

Average age group

> 35

> 35

Pros and Cons

VAP

DRUG

Pros

  • Higher exposure to AU market

  • Lower management fee

  • Higher distribution yield

  • Higher exposure to US market

  • Higher price growth

Cons

  • Lower exposure to US market

  • Lower price growth

  • Lower exposure to AU market

  • Higher management fee

  • Lower distribution yield

VAP

DRUG

Higher exposure to AU market

Lower exposure to AU market

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield